Asston Pharmaceuticals shareholders and shareholding pattern
BSE: 544445Pharmaceuticals & BiotechnologySmall Cap
ASSTON PHARMACEUTICALS LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2025
Last close ₹141.08up ₹6.64 (4.94%)
Share price at the BSE close on 27 Oct 2026. Previous close ₹134.44.
27 Oct: open ₹129.99, high ₹141.16, low ₹129.99
52-week range of traded prices to 27 Oct 2026
₹60.00Low, 21 Jul 2026₹141.16High, 27 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹154 Cr3,188th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 298.06
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 39.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 1.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 9.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.13
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 84,000
Asston Pharmaceuticals' shareholding pattern for Sep 2026, filed on 21 Oct 2026, with every filing from Mar 2026: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Asston Pharmaceuticals, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters39.48%
- Foreign institutionsNone
- Individuals and others60.52%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Individuals and others
| Per cent | Mar 2026 | Sep 2026 |
|---|---|---|
| 50.66% | 39.48% | |
| Indian promoters | 50.66% | 39.48% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 49.34% | 60.52% |
| Shares in issue | 85,12,360 | 1,09,22,791 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 62,71,360 | 54,69,227 |
| Promoters' shares locked in | 43,12,480 | 30,09,740 |
A dash is a line the filing did not state.
Asston Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is SAILI JAYARAM MORE, 16.96%.
| Holder | |||
|---|---|---|---|
| SAILI JAYARAM MOREIndividuals and Hindu undivided families | 16.96% | 18,52,856 | 73.03% |
| ASHISH NARAYAN SAKALKARIndividuals and Hindu undivided families | 16.96% | 18,52,856 | 73.03% |
| SACHIN CHANDRAKANT BADAKHIndividuals and Hindu undivided families | 5.56% | 6,06,768 | 50.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Asston Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Mar 2026 | Sep 2026 |
|---|---|---|
| VIJAY RATHEEResident individuals, over ₹2 lakh at face value | – | 12.06% |
| VIJAYLAXMI INFRA PROJECTS PRIVATE LIMITEDCompanies | – | 7.16% |
| PRAKRUTI R PALIResident individuals, over ₹2 lakh at face value | – | 7.05% |
| MAHESH VISHNUPANT MULAYResident individuals, over ₹2 lakh at face value | 2.91% | 2.36% |
| KULDIP SINGH RATHEEResident individuals, over ₹2 lakh at face value | 2.35% | 1.83% |
| SNEHLATA MANOJ KATHOTIAResident individuals, over ₹2 lakh at face value | – | 1.43% |
| VRUSHALI YOGESH SUPEKARResident individuals, over ₹2 lakh at face value | 1.46% | 1.14% |
| MINERVA VENTURES FUNDForeign portfolio investors, category I | 1.91% | – |
| DILIP RAMESHCHANDRA JAGADResident individuals, over ₹2 lakh at face value | 1.25% | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.
Who moved in the Sep 2026 filing
Against the Sep 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Individuals and others: VIJAY RATHEE newly named at 12.06%; SNEHLATA MANOJ KATHOTIA 1.43%, −0.08 pts